Results 261 to 270 of about 1,277,672 (355)

Porphyromonas gingivalis GroEL exacerbates orthotopic allograft transplantation vasculopathy via impairment of endothelial cell function

open access: yesMolecular Oral Microbiology, EarlyView.
Abstract Orthotopic allograft transplantation (OAT) is a significant approach to addressing organ failure. However, persistent immune responses to the allograft affect chronic rejection, which induces OAT vasculopathy (OATV) and organ failure. Porphyromonas gingivalis can infiltrate remote organs via the bloodstream, thereby intensifying the severity ...
Chien‐Sung Tsai   +7 more
wiley   +1 more source

Imaging modalities used in follow-up after coil embolization of splenic artery aneurysm - a systematic review. [PDF]

open access: yesPol J Radiol
Lamparski KJ   +7 more
europepmc   +1 more source

Porphyromonas gingivalis GroEL accelerates abdominal aortic aneurysm formation by matrix metalloproteinase‐2 SUMOylation in vascular smooth muscle cells: A novel finding for the activation of MMP‐2

open access: yesMolecular Oral Microbiology, EarlyView.
Abstract Infection is a known cause of abdominal aortic aneurysm (AAA), and matrix metalloproteases‐2 (MMP‐2) secreted by vascular smooth muscle cells (SMCs) plays a key role in the structural disruption of the middle layer of the arteries during AAA progression.
Yi‐Wen Lin   +6 more
wiley   +1 more source

Pulsed Field Ablation for Atrial Fibrillation in Patients With Obesity: Procedural and Clinical Outcomes

open access: yesPacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Background Procedural and clinical outcomes in patients with obesity undergoing catheter ablation for atrial fibrillation (AF) have been mixed. Clinical data in the context of pulsed field ablation (PFA) are currently limited in this patient cohort.
Francis J. Ha   +6 more
wiley   +1 more source

Evaluating VEGFR2 as a Target for Anti‐Tumour Therapy in Canine Melanoma

open access: yesVeterinary and Comparative Oncology, EarlyView.
ABSTRACT Vascular endothelial growth factor receptor 2 (VEGFR2) is a key target for anti‐angiogenic oncotherapy, as inhibiting this receptor on tumour vasculature slows tumour development and enhances drug‐ and immune infiltration, improving therapy outcome.
Esther Hindriks   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy